{"prompt": "['MCW', 'OUTPATIENT', 'CPX-351', 'TRIAL', '8.6 CONTINUING PROGRESS REPORTS', '54', '8.7 CAP, CLIA, AND REFERENCE RANGES', '55', '8.8 SCIENTIFIC REVIEW COMMITTEE', '55', '8.9 DATA AND SAFETY MONITORING COMMITTEE', '56', '8.10 SUBJECT CONFIDENTIALITY AND ACCESS TO SOURCE DOCUMENTS/DATA', '56', '8.11 RISK MANAGEMENT', '57', '8.11.1 Risk Assessment, Control and Review', '57', '8.11.2 Safety Run-In Phase and Continuation Phase', '57', '8.11.3 Protection from Unnecessary Harm', '58', '8.12 CHANGES IN THE PROTOCOL, CONSENT OR OTHER TRIAL DOCUMENT', '58', '9 STATISTICAL CONSIDERATIONS', '58', '9.1 AIMS', '58', '9.2 SAMPLE SIZE DETERMINATION AND POWER ESTIMATE', '59', '9.3 SUBJECT REPLACEMENT', '59', '9.4 STOPPING RULES', '59', '9.5 INTERIM ANALYSIS', '60', '9.6 ANALYSIS METHOD', '60', '10 REFERENCES', '63', 'APPENDIX 1: PERFORMANCE STATUS CRITERIA', '65', 'APPENDIX 2: LOST TO FOLLOW-UP LETTER', '66', 'APPENDIX 3: PRESCREENING LOG', '68', 'APPENDIX 4: NURSE TEACHER EDUCATION PROGRAM VALIDATION GUIDE', '69', 'APPENDIX 5: STUDY DIARY', '70', 'APPENDIX 6: PATIENT-REPORTED OUTCOME MEASURES', '78', 'MCW Protocol No: IIT-Michaelis-OutpatientCPX-351', 'p6', 'Version No.: 3', 'Version Date: 04/15/2020']['MCW', 'OUTPATIENT', 'CPX-351', 'TRIAL', 'PROTOCOL SUMMARY', 'A multi-institutional, phase IV project to study the feasibility of safely', 'Title', 'managing patients receiving induction with liposomal daunorubicin', 'and cytarabine (CPX-351) for acute myeloid leukemia (AML) in an', 'outpatient environment', 'Sponsor', 'Laura C. Michaelis, MD (Medical College of Wisconsin)', 'Principal', 'Laura C. Michaelis, MD', 'Investigator', 'Clinical Trial Phase', 'Phase IV', 'Adults with newly diagnosed therapy-related acute myeloid leukemia', 'Study Population', '(t-AML) or AML with myelodysplasia-related changes (AML-MRC)', 'To estimate the feasibility of an outpatient care model for induction', 'Primary Aim', 'and management of patients with AML who receive induction therapy', 'with liposomal daunorubicin and cytarabine (CPX-351).', '1. To estimate the overall inpatient time for subjects who receive', 'CPX-351 induction as an outpatient.', '2. To estimate the incidence of admission to an intensive care unit in', 'subjects treated in an outpatient environment.', '3. To estimate the incidence of 30-day all-cause mortality in subjects', 'treated in an outpatient model', '4. To estimate the incidence of 60-day all-cause mortality in subjects', 'treated in an outpatient model.', '5. To describe the health care resource utilization for subjects', 'Secondary Aims', 'induced with an outpatient care model.', '6. To assess the health-related quality of life, anxiety levels and', 'treatment-related worry for subjects receiving induction', 'chemotherapy in an outpatient environment immediately prior to', 'induction, 7-10 days following induction and 30 and 60 days after', 'induction.', '7. To assess the health-related quality of life anxiety levels and', 'treatment-related worry for the primary caregiver of subjects', 'receiving induction chemotherapy in an outpatient environment', 'immediately prior to induction, 7-10 days following induction and', '30 and 60 days after induction.', 'MCW Protocol No: IIT-Michaelis-OutpatientCPX-351', 'p7', 'Version No.: 3', 'Version Date: 04/15/2020']['MCW', 'OUTPATIENT', 'CPX-351', 'TRIAL', 'Single-arm, multicenter run-in phase (six subjects), multicenter', 'Study Design', 'continuation phase (114 subjects), Phase IV study.', 'CPX-351 is administered, according to FDA approval, to subjects who', 'meet medical and logistical criteria for study enrollment. The study', 'intervention is the application of a prescribed outpatient care model,', 'Intervention', 'including a nurse teacher educational program and quality of life', 'Description', 'surveys for both subjects and caregivers. Induction therapy and', 'medical follow up are performed without prophylactic admission to an', 'inpatient facility.', 'Number of Subjects', '120 subjects (6 for run-in phase, 114 for continuation phase)', 'Subject', 'Participation', '60 days', 'Duration', 'Estimated Time to', 'Complete', '24 months', 'Enrollment:', 'MCW Protocol No: IIT-Michaelis-OutpatientCPX-351', 'p8', 'Version No.: 3', 'Version Date: 04/15/2020']\n\n###\n\n", "completion": "END"}